Virtual screening of LPXTG competitive SrtA inhibitors targeting signal transduction mechanism in Bacillus anthracis: a combined experimental and theoretical study.
Members of the sortase enzyme super family decorate the surfaces of Bacillus anthracis cell wall with proteins that play key roles in microbial pathogenesis and its biofilm formation. Bacillus anthracis Sortase-A (Ba-SrtA) is a potential target for new therapeutics as it is required for B. anthracis survival and replication within macrophages. An understanding of the binding site pocket and substrate recognition mechanism by SrtA enzymes may serve to be beneficial in the rational development of sortase inhibitors. Here, the LPXTG signal peptide-based competitive inhibitors are screened against the Ba-SrtA and compounds with reasonable inhibition, specificity, and mechanisms of inactivation of SrtA have been covered. The screened compounds are experimentally validated against the phylogenetically similar Gram-positive pathogen B. cereus. In situ microscopic visualizations suggest that these screened compounds showed the microbial and biofilm inhibitory activity against B. cereus. It facilitates the further development of these molecules into useful anti-infective agents to treat infections caused by B. anthracis and other Gram-positive pathogens. These results provide insight into basic design principles for generating new clinically relevant lead molecules. It also provides an alternative strategy where a screened ligand molecule can be used in combination to battle increasingly against the Gram-positive pathogens.
Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University , Karaikudi, Tamil Nadu , India and.
Chandrabose
C
Selvaraj
Jeyachandran
J
Sivakamavalli
Vaseeharan
V
Baskaralingam
Sanjeev Kumar
SK
Singh
D019881:Aminoacyltransferases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology; D001408:Bacillus anthracis / Q000187:drug effects / Q000502:physiology*; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D003198:Computer Simulation; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical; D008956:Models, Chemical; D010455:Peptides / Q000737:chemistry* / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D010455:Peptides; D019881:Aminoacyltransferases; C120542:sortase A; D003546:Cysteine Endopeptidases
Bacillus anthracis; CLSM; SrtA; signaling mechanism; virtual screening